Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors
Titel:
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors
Auteur:
Moore, M. Hirte, H.W. Siu, L. Oza, A. Hotte, S.J. Petrenciuc, O. Cihon, F. Lathia, C. Schwartz, B.